Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Health Discovery Appoints John A. Norris As COO
“We are extremely fortunate to have attracted someone of John Norris’ caliber,” said Stephen D. Barnhill, M.D., chairman and CEO of Health Discovery. “We expect that his extensive
“We are extremely fortunate to have attracted someone of John Norris’ caliber,” said Stephen D. Barnhill, M.D., chairman and CEO of Health Discovery. “We expect that his extensive
Jennerex has disclosed the second and final closing of a private placement financing with aggregate gross proceeds of $5.6m exceeding the target of $5m. As previously reported by
Millennium has announced that the FDA has granted priority review to the company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data
Zila has announced the completion of the merger with a subsidiary of TOLMAR Holding. Pursuant to the merger agreement between the companies, at the effective time of the
The US Patent and Trademark Office has granted a patent to Resolvyx Pharmaceuticals for its chronic dry eye syndrome treatment, RX-10045. RX-10045 has been formulated as a topical
Wyeth Pharmaceuticals has announced the formation of a worldwide alliance to discover, develop, and commercializes protein drug candidates for three undisclosed targets in multiple therapeutic areas. The alliance
Boston Scientific has completed patient enrollment in the workhorse portion of its PLATINUM clinical program. The trial enrolled 1,532 patients with up to two de novo lesions at
NewCardio has closed a private placement financing with institutional and other accredited investors, including members of NewCardio’s management team and board of directors, who purchased over half of
Cambridge Regulatory Services (CambReg) has formed a strategic alliance with SIRO Clinpharm, a clinical research organisation. The new alliance will provide benefits to pharma companies in both Asia
Arena Pharmaceuticals has disclosed results from the Behavioral modification and Lorcaserin second study for obesity management trial (BLOSSOM). BLOSSOM confirms the results previously reported for the Behavioral modification